State Street SPDR S&P Biotech ETF
180 hedge funds and large institutions have $2.76B invested in State Street SPDR S&P Biotech ETF in 2015 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 48 increasing their positions, 47 reducing their positions, and 11 closing their positions.
355% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 11
43% more funds holding in top 10
Funds holding in top 10: 7 → 10 (+3)
28% more capital invested
Capital invested by funds: $2.16B → $2.76B (+$603M)
23% more funds holding
Funds holding: 146 → 180 (+34)
2% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 47
65% less call options, than puts
Call options by funds: $245M | Put options by funds: $701M
74.31% less ownership
Funds ownership: 463.38% → 389.07% (-74%)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$107M |
| 2 |
Citigroup
New York
|
+$106M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$105M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$68.5M |
| 5 |
Goldman Sachs
New York
|
+$67.2M |
Top Sellers
| 1 |
JP Morgan Chase
New York
|
-$190M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$178M |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$16.6M |
| 4 |
SCM
Sandler Capital Management
New York
|
-$8.13M |
| 5 |
VF
Virtu Financial
New York
|
-$5.51M |
XBI Hedge Fund Activity: Q1 2015 in Review
180 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q1 2015, worth a combined $2.76B — up 28% from $2.16B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new XBI positions and 11 closed out — a net gain of 39 holders — while 48 added to existing stakes and 47 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $107M. The largest seller was JP Morgan Chase, cutting an estimated $190M.
- 180 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q1 2015, up from 146 in Q4 2014.
- Funds reported $2.76B of State Street SPDR S&P Biotech ETF stock for Q1 2015, up 28% quarter-over-quarter.
- 50 funds opened new State Street SPDR S&P Biotech ETF positions in Q1 2015 and 11 closed out, a net change of +39 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q1 2015 was Morgan Stanley, an estimated $107M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q1 2015 was JP Morgan Chase, an estimated $190M sold.
Based on aggregated 13F filings for Q1 2015.